Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Indiana University
Nationwide Children's Hospital
Turning Point Therapeutics, Inc.
Hoffmann-La Roche
CHA University
National Institutes of Health Clinical Center (CC)
OHSU Knight Cancer Institute
Assistance Publique - Hôpitaux de Paris
Ann & Robert H Lurie Children's Hospital of Chicago
St. Jude Children's Research Hospital